company background image
WBIO

Wockhardt Bio BRSE:WBIO Stock Report

Last Price

CHF1.51

Market Cap

CHF78.4m

7D

0%

1Y

n/a

Updated

16 Aug, 2022

Data

Company Financials
WBIO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

WBIO Stock Overview

Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, and markets pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally.

Wockhardt Bio Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wockhardt Bio
Historical stock prices
Current Share PriceCHF1.51
52 Week HighCHF3.26
52 Week LowCHF0.85
Beta-10.8
1 Month Change-10.12%
3 Month Changen/a
1 Year Changen/a
3 Year Change619.05%
5 Year Changen/a
Change since IPO-70.10%

Recent News & Updates

Shareholder Returns

WBIOCH BiotechsCH Market
7D0%1.3%0.08%
1Yn/a-14.1%-12.9%

Return vs Industry: Insufficient data to determine how WBIO performed against the Swiss Biotechs industry.

Return vs Market: Insufficient data to determine how WBIO performed against the Swiss Market.

Price Volatility

Is WBIO's price volatile compared to industry and market?
WBIO volatility
WBIO Average Weekly Movementn/a
Biotechs Industry Average Movement13.0%
Market Average Movement4.5%
10% most volatile stocks in CH Market7.8%
10% least volatile stocks in CH Market2.4%

Stable Share Price: Insufficient data to determine WBIO's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine WBIO's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a50n/ahttps://www.wockhardtbio.com

Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, and markets pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally. The company’s products cover various therapeutic categories, including central nervous system agents, hormones and related agents, cardiovascular agents, anti-infective agents, and respiratory agents, as well as other agents, such as gastrointestinal, dermatological, and biological (vaccines) agents. It also exports its products to approximately 50 countries worldwide.

Wockhardt Bio Fundamentals Summary

How do Wockhardt Bio's earnings and revenue compare to its market cap?
WBIO fundamental statistics
Market CapCHF78.44m
Earnings (TTM)-CHF2.82m
Revenue (TTM)CHF282.39m

0.3x

P/S Ratio

-27.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
WBIO income statement (TTM)
RevenueUS$297.12m
Cost of RevenueUS$133.64m
Gross ProfitUS$163.48m
Other ExpensesUS$166.45m
Earnings-US$2.97m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.057
Gross Margin55.02%
Net Profit Margin-1.00%
Debt/Equity Ratio21.1%

How did WBIO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is WBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WBIO?

Other financial metrics that can be useful for relative valuation.

WBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA100.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does WBIO's PS Ratio compare to its peers?

WBIO PS Ratio vs Peers
The above table shows the PS ratio for WBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.8x
BSLN Basilea Pharmaceutica
3.2x11.5%CHF476.9m
KURN Kuros Biosciences
3.9xn/aCHF58.7m
ADXN Addex Therapeutics
5.2x-79.1%CHF12.9m
RLF Relief Therapeutics Holding
41.6x53.2%CHF137.1m
WBIO Wockhardt Bio
0.3xn/aCHF78.4m

Price-To-Sales vs Peers: WBIO is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (13.8x).


Price to Earnings Ratio vs Industry

How does WBIO's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Sales vs Industry: WBIO is good value based on its Price-To-Sales Ratio (0.3x) compared to the Swiss Biotechs industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is WBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate WBIO's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of WBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: WBIO (CHF1.51) is trading below our estimate of fair value (CHF27.5)

Significantly Below Fair Value: WBIO is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Wockhardt Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


40.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Wockhardt Bio is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Wockhardt Bio competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Wockhardt Bio performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


48.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: WBIO is currently unprofitable.

Growing Profit Margin: WBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: WBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 48.8% per year.

Accelerating Growth: Unable to compare WBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: WBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.1%).


Return on Equity

High ROE: WBIO has a negative Return on Equity (-1.06%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Wockhardt Bio's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: WBIO's short term assets ($308.1M) do not cover its short term liabilities ($317.5M).

Long Term Liabilities: WBIO's short term assets ($308.1M) exceed its long term liabilities ($33.1M).


Debt to Equity History and Analysis

Debt Level: WBIO's net debt to equity ratio (7.4%) is considered satisfactory.

Reducing Debt: WBIO's debt to equity ratio has reduced from 103.8% to 21.1% over the past 5 years.

Debt Coverage: WBIO's debt is well covered by operating cash flow (111.6%).

Interest Coverage: Insufficient data to determine if WBIO's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Wockhardt Bio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate WBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate WBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if WBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if WBIO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: WBIO is not paying a notable dividend for the Swiss market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as WBIO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Wockhardt Bio has no CEO, or we have no data on them.


Board Members

Experienced Board: WBIO's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Wockhardt Bio AG's employee growth, exchange listings and data sources


Key Information

  • Name: Wockhardt Bio AG
  • Ticker: WBIO
  • Exchange: BRSE
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CHF78.441m
  • Shares outstanding: 51.95m
  • Website: https://www.wockhardtbio.com

Number of Employees


Location

  • Wockhardt Bio AG
  • Grafenauweg 6
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.